News

As part of the joint venture agreement, Labopharm is expected to grant Angelini Labopharm the exclusive right to market and sell Oleptro in the US. The joint venture,

MWV has posted a net income of $24m for the first quarter of 2010, or $0.14 per diluted share, compared to net loss of $79m, or $0.46 per

Caldolor is used primarily in hospitalised patients who are unable to receive oral therapies for pain relief and fever reduction. If approved for marketing in Canada, it would

AstraZeneca posted a net income of $2.77bn for the first quarter of 2010, compared to $2.14bn for the prior year period. Operating income was $3.64bn, compared to $3.16bn

Galapagos’ service division BioFocus is expected to perform the research and eligible to receive $41m (EUR31m) in research fees during the five-year collaboration. BioFocus is expected to apply

LifeCodexx aims to establish ‘Next Generation Molecular Diagnostics’ in Europe. This will provide improved diagnostics for targeted, cost-efficient treatments. The test development currently being undertaken also receives public

In a double-blind, active-controlled Phase II study of 480 randomised subjects, the safety, tolerability and immunogenicity of a single 15microgram dose or 60microgram dose (per strain) of trivalent

Applied BioCode’s Barcoded Magnetic Beads digital multiplexing technology, along with the BioCode-1000 Analyzer for barcode and fluorescence detection, results in a flexible digital multiplexing platform suited for a

Roche’s T-emerge Phase III clinical trials are designed as multicenter, multi-country, randomized, controlled (active or placebo), double-blind and open studies. Over 6,000 patients will be enrolled in the